Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 10.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of EPRX.TO is 15 and suggests 36% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only
Buy
Sell